entertainment -WSS

entertainment

author：hotspot 2025-09-29 21:12:48 - browse：17518

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Paying for Covid pills will soon shift to insurers

leisure time

WSS

Drinking water from half of US faucets contains PFAS: Study

Maker of FluMist seeks to allow at

Readout Newsletter: XBI biotech index, Akero Therapeutics

Testing for cancer recurrence creates a new limbo for patients

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

leisure time

entertainment

focus

Novavax promises a turnaround & Lilly roils the obesity market

First Opinion Podcast: How to protect health care in times of war

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Neutralizing antibodies against HIV shows promise in children

Walensky prepares to leave CDC — and Congress — behind

How corporate America is slashing DEI workers amid backlash to diversity programs

Heart attack and stroke risk calculators need revising

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Virginia high school admissions case could be legal follow

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

explore

Testing for cancer recurrence creates a new limbo for patients

Why Sanofi got shellacked over its spinoff

Senate panel to vote on hospitals, PBMs, prisoner care

With fresh data, a dynamic duo powers Eli Lilly to new heights

What to know about a major upcoming Wegovy heart health study

Neutralizing antibodies against HIV shows promise in children

focus

leisure time

leisure time

knowledge